ArticlePloS one2025
An innovative submucosal filler for esophageal endoscopic submucosal dissection: A porcine model study (with video).
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEsophageal endoscopic submucosal dissection (ESD) a more challenging procedure. Numerous studies have explored submucosal injection materials from diverse perspectives. However, there is no consensus yet, and further exploration is still required. This study aimed to evaluate the efficacy of a novel submucosal filler, acetylcysteine, which is commonly used in respiratory medicine, when applied for the first time in ESD procedure of the porcine esophagus.
methodsA self-controlled survival study was carried out on porcine model. In each pig, the novel submucosal filler was injected in one part of the esophagus (Experimental group; Group E), while normal saline was injected in another part (Control group; Group C) during the ESD procedure. Additionally, one pig received a submucosal injection of normal saline as a negative control to observe baseline daily movements and pathology following ESD. One month post- ESD, endoscopic and pathological evaluations were conducted to assess wound healing and other vital organs, allowing for a comprehensive assessment of the long - term impact and efficacy of the filler in this novel application context.
resultsThe dissection time per unit area in Group E was notably shorter than in Group C (3.79 ± 1.38 minutes vs. 5.79 ± 1.22 minutes; P = 0.004). Group E also required a smaller volume of submucosal filler per unit area than Group C (3.48 ± 1.07 ml vs. 7.48 ± 3.96 ml; P = 0.039). However, There were no significant differences between Group E and Group C regarding the complication rate and thickness of the submucosal layer in the ESD specimens. Pathological evaluation of wound healing and other vital organs demonstrated comparable results in Group E and Group C.
conclusionThis novel submucosal filler can expedite the ESD process without increasing the incidence of complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.